LGND Quote, Financials, Valuation and Earnings

Dare Bioscience has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of -17219.13%. Ligand Pharmaceuticals's return on equity of -16.38% beat Dare Bioscience's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 27.84%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 350.61%. Given that Dare Bioscience has higher upside potential than Ligand Pharmaceuticals, analysts believe Dare Bioscience is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 0.860, which suggesting that the stock is 14.038% less volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.202, suggesting its more volatile than the S&P 500 by 20.169%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Ligand Pharmaceuticals's net income of -$42.5M is lower than Dare Bioscience's net income of -$4.4M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.57x versus 940.71x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of 50.24%. Ligand Pharmaceuticals's return on equity of -16.38% beat Johnson & Johnson's return on equity of 30.18%.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 27.84%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 11.03%. Given that Ligand Pharmaceuticals has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals has a beta of 0.860, which suggesting that the stock is 14.038% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.29% to investors and pays a quarterly dividend of $1.30 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Ligand Pharmaceuticals's net income of -$42.5M is lower than Johnson & Johnson's net income of $11B. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Johnson & Johnson's PE ratio is 16.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.57x versus 4.14x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of 21.68%. Ligand Pharmaceuticals's return on equity of -16.38% beat Eli Lilly and's return on equity of 78.25%.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 27.84%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 20.31%. Given that Ligand Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Ligand Pharmaceuticals is more attractive than Eli Lilly and.

Ligand Pharmaceuticals has a beta of 0.860, which suggesting that the stock is 14.038% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Ligand Pharmaceuticals's net income of -$42.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Eli Lilly and's PE ratio is 64.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.57x versus 14.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of -49.65%. Ligand Pharmaceuticals's return on equity of -16.38% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 27.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 37.5%. Given that NovaBay Pharmaceuticals has higher upside potential than Ligand Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 0.860, which suggesting that the stock is 14.038% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ligand Pharmaceuticals's net income of -$42.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.57x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.